{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:52:37Z","timestamp":1782489157145,"version":"3.54.5"},"reference-count":142,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Direcci\u00f3n General de Investigaciones of Universidad Santiago de Cali","award":["DGI-01-2025"],"award-info":[{"award-number":["DGI-01-2025"]}]},{"name":"Direcci\u00f3n General de Investigaciones of Universidad Santiago de Cali","award":["DGI-02-2025"],"award-info":[{"award-number":["DGI-02-2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Plasma cell myeloma (PCM) is classified as a blood cancer and is characterized by the abnormal proliferation of plasma cells in the bone marrow and the excessive production of monoclonal immunoglobulins, which lead to permanent damage to vital organs. Although treatment strategies have improved with the development of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies (mAbs), PCM remains an incurable disease due to its molecular heterogeneity and the development of drug resistance. In this review, we discuss the biochemical and molecular foundations underlying the diagnosis and treatment of PCM, emphasizing both traditional and advanced approaches. Classical methods such as serum protein electrophoresis (SPEP), immunofixation electrophoresis (IFE), and serum free light chain (sFLC) determination are highlighted alongside their integration with highly sensitive techniques like mass spectrometry (MS) and next-generation sequencing (NGS). Special attention is given to nanotechnology-based systems, including liposomes, polymeric nanoparticles (NPs), dendrimers, and hybrid nanocapsules, which enable controlled drug release, targeted delivery, and the minimization of systemic toxicity. Increasingly, nanomaterials are being shown to greatly enhance the biodistribution and pharmacokinetics of anticancer drugs, leading to improved therapeutic effects and escaping resistance mechanisms by employing multifunctional strategies that include dual drug co-encapsulation, pH-sensitive release and theranostic applications. Furthermore, the integration of nanotechnology with immunotherapy platforms represents a paradigm shift toward precision and personalized medicine for the treatment of PCM. Overall, this review views nanotechnology as an enabling technology to improve therapeutic effectiveness, minimize toxicity and open new avenues toward next-generation smart and personalized therapeutics for the treatment of PCM.<\/jats:p>","DOI":"10.3390\/pharmaceutics17121570","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:11:24Z","timestamp":1764947484000},"page":"1570","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Plasma Cell Myeloma: Biochemical Insights into Diagnosis, Treatment, and Smart Nanocarrier-Based Therapeutic Development"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7456-406X","authenticated-orcid":false,"given":"Lizeth Geraldine","family":"Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Research Group of Electrochemistry and Environment (GIEMA), Faculty of Basic Sciences, Universidad Santiago de Cali, Cali 760035, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-7354","authenticated-orcid":false,"given":"Sixta Palencia","family":"Luna","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences and Chemical, Faculty of Sciences, Universidad San Sebasti\u00e1n, Lientur 1457, Concepci\u00f3n 4030000, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6209-4688","authenticated-orcid":false,"given":"Andr\u00e9s Felipe","family":"Chamorro","sequence":"additional","affiliation":[{"name":"Research Group of Electrochemistry and Environment (GIEMA), Faculty of Basic Sciences, Universidad Santiago de Cali, Cali 760035, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/BLCTT.S272703","article-title":"Differential diagnosis and therapeutic advances in multiple myeloma: A review article","volume":"13","author":"Hussain","year":"2023","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10585-024-10305-2","article-title":"Multiple myeloma: Clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics","volume":"41","author":"Elbahoty","year":"2024","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_4","unstructured":"American Cancer Society (2025, June 01). Key Statistics for Multiple Myeloma. Available online: https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/about\/key-statistics.html."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"B\u0119bnowska, D., Hrynkiewicz, R., Grywalska, E., Pasiarski, M., Sosnowska-Pasiarska, B., Smarz-Widelska, I., and Nied\u017awiedzka-Rystwej, P. (2021). Immunological prognostic factors in multiple myeloma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073587"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e36660","DOI":"10.1097\/MD.0000000000036660","article-title":"New diagnostic strategy for multiple myeloma: A review","volume":"102","author":"Xu","year":"2023","journal-title":"Medicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_9","first-page":"47","article-title":"Onconephrology: The intersections between the kidney and cancer","volume":"71","author":"Rosner","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.21037\/tcr.2020.02.77","article-title":"Impact of oral mucositis on quality of life in patients undergoing oncological treatment: A systematic review","volume":"9","author":"Gopinath","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rehan, F., Zhang, M., Fang, J., and Greish, K. (2024). Therapeutic applications of nanomedicine: Recent developments and future perspectives. Molecules, 29.","DOI":"10.3390\/molecules29092073"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.canlet.2017.11.020","article-title":"Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments","volume":"414","author":"Hu","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Radhakrishnan, V., Golla, U., and Kudva, A.K. (2024). Role of immune cells and immunotherapy in multiple myeloma. Life, 14.","DOI":"10.3390\/life14040461"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cardona, Y.V., Mu\u00f1oz, L.G., Cardozo, D.G., and Chamorro, A.F. (2024). Recent applications of amphiphilic copolymers in drug release systems for skin treatment. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16091203"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/17474086.2018.1489718","article-title":"Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic","volume":"11","author":"Morgan","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bain, B.J., and Leach, M. (2021). Immunophenotyping for Haematologists: Principles and Practice, John Wiley & Sons. Available online: https:\/\/books.google.com.co\/books?id=UWj-DwAAQBAJ.","DOI":"10.1002\/9781119606161"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Calder\u00f3n, C.B., Sierro-Mart\u00ednez, B., Garc\u00eda-Guerrero, E., Sanoja-Flores, L., Mu\u00f1oz-Garc\u00eda, R., Ruiz-Maldonado, V., and Caballero-Vel\u00e1zquez, T. (2023). Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1152498"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13046-024-03217-2","article-title":"The FGF\/FGFR\/c-Myc axis as a promising therapeutic target in multiple myeloma","volume":"43","author":"Giacomini","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.pmbts.2018.04.002","article-title":"An introduction to epigenetic mechanisms","volume":"158","author":"Radford","year":"2018","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Caprio, C., Sacco, A., Giustini, V., and Roccaro, A.M. (2020). Epigenetic aberrations in multiple myeloma. Cancers, 12.","DOI":"10.3390\/cancers12102996"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Handa, H., Murakami, Y., Ishihara, R., Kimura-Masuda, K., and Masuda, Y. (2019). The role and function of microRNA in the pathogenesis of multiple myeloma. Cancers, 11.","DOI":"10.3390\/cancers11111738"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"De Smedt, E., Lui, H., Maes, K., De Veirman, K., Menu, E., Vanderkerken, K., and De Bruyne, E. (2018). The epigenome in multiple myeloma: Impact on tumor cell plasticity and drug response. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00566"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Mbemi, A., Khanna, S., Njiki, S., Yedjou, C.G., and Tchounwou, P.B. (2020). Impact of gene\u2013environment interactions on cancer development. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17218089"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: Mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4103\/mgmj.mgmj_132_25","article-title":"Non-secretory myeloma: Clinical profile and diagnostic utility of immunohistochemistry and free light chain assay in a rare variant of plasma cell myeloma","volume":"12","author":"Trisal","year":"2025","journal-title":"MGM J. Med. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.14740\/jocmr3383w","article-title":"Serum free light chains in neoplastic monoclonal gammopathies: Relative under-detection of lambda dominant kappa\/lambda ratio, and underproduction of free lambda light chains, as compared to kappa light chains, in patients with neoplastic monoclonal gammopathies","volume":"10","author":"Lee","year":"2018","journal-title":"J. Clin. Med. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17118","article-title":"The detection of circulating plasma cells may improve the revised international staging system (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma","volume":"193","author":"Galieni","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cpt.2023.12.004","article-title":"Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology","volume":"2","author":"Wang","year":"2024","journal-title":"Cancer Pathog. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Misiewicz-Krzeminska, I., Krzeminski, P., Corchete, L.A., Quwaider, D., Rojas, E.A., Herrero, A.B., and Guti\u00e9rrez, N.C. (2019). Factors regulating microRNA expression and function in multiple myeloma. Non-Coding RNA, 5.","DOI":"10.3390\/ncrna5010009"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/ijc.ijc_51_24","article-title":"IPD regimen effect on the levels of VEGF and IL-6 in elderly patients with recurrent multiple myeloma","volume":"62","author":"Zhao","year":"2025","journal-title":"Indian J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1158\/1078-0432.CCR-21-0649","article-title":"A personalized mass spectrometry\u2013based assay to monitor M-protein in patients with multiple myeloma (EasyM)","volume":"27","author":"Liyasova","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Hughes, A.M., Kuek, V., Kotecha, R.S., and Cheung, L.C. (2022). The bone marrow microenvironment in B-cell development and malignancy. Cancers, 14.","DOI":"10.3390\/cancers14092089"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chen, J.H., Hsu, S.N., Huang, T.C., Wu, Y.Y., Lin, C., Chang, P.Y., and Ho, C.L. (2015). Prognostic significance of initial serum albumin and 24-hour daily protein excretion before treatment in multiple myeloma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128905"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Hern\u00e1ndez, M.D., Periago, A., Vasco-Mogorr\u00f3n, M.A., Campillo, J.A., Caba\u00f1as, V., Berenguer, M., and Minguela, A. (2021). Proliferation to apoptosis tumor cell ratio as a biomarker to improve clinical management of pre-malignant and symptomatic plasma cell neoplasms. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083895"},{"key":"ref_39","unstructured":"Fern\u00e1ndez, J.E. (2022). Estudio de la Funci\u00f3n de Rnd3 en el Mieloma M\u00faltiple. [Doctoral Dissertation, Universidad CEU-Cardenal Herrera]. Available online: https:\/\/hdl.handle.net\/10637\/13982."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Harmer, D., Falank, C., and Reagan, M.R. (2019). Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00788"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"155358","DOI":"10.1016\/j.cyto.2020.155358","article-title":"Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels","volume":"138","author":"Gu","year":"2021","journal-title":"Cytokine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"155271","DOI":"10.1016\/j.cyto.2020.155271","article-title":"Cytokine profile in multiple myeloma","volume":"136","author":"Jasrotia","year":"2020","journal-title":"Cytokine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41408-023-00817-7","article-title":"Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma","volume":"13","author":"Evers","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ria, R., Melaccio, A., Racanelli, V., and Vacca, A. (2020). Anti-VEGF drugs in the treatment of multiple myeloma patients. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061765"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.25117","article-title":"Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Rajkumar","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_46","first-page":"864","article-title":"Serum protein electrophoresis and immunofixation electrophoresis detection in multiple myeloma","volume":"30","author":"Zhu","year":"2021","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ying, L., Zhang, X., Lu, N., Zhao, L., Nie, Y., Wang, G., and Xu, L. (2023). Evaluating the screening value of serum light chain ratio, \u03b22 microglobulin, lactic dehydrogenase and immunoglobulin in patients with multiple myeloma using ROC curves. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0281743"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","article-title":"Multiple myeloma minimal residual disease detection: Targeted mass spectrometry in blood vs next-generation sequencing in bone marrow","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1039\/D0BM00772B","article-title":"Advancements in nanotechnology for the diagnosis and treatment of multiple myeloma","volume":"8","author":"Zhong","year":"2020","journal-title":"Biomater. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clinbiochem.2017.05.001","article-title":"Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"51","author":"Willrich","year":"2018","journal-title":"Clin. Biochem."},{"key":"ref_51","unstructured":"Ramakrishnan, N., and Jialal, I. (2019). Bence-Jones Protein. StatPearls, StatPearls Publishing. Available online: https:\/\/europepmc.org\/article\/nbk\/nbk541035."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lawler, K., and Kijanka, G. (2017). Clinical applications of immunoassays. Immunoassays, Jenny Stanford Publishing.","DOI":"10.1201\/9781315206547-6"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12288-015-0605-3","article-title":"Old but still relevant: High resolution electrophoresis and immunofixation in multiple myeloma","volume":"32","author":"Misra","year":"2016","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_54","first-page":"570","article-title":"Biochemical profile of Bence-Jones type multiple myeloma","volume":"67","author":"Lyubimova","year":"2022","journal-title":"Klin. Lab. Diagn."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-23-2767","article-title":"Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)","volume":"30","author":"Fan","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101142","DOI":"10.1016\/j.beha.2020.101142","article-title":"Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood","volume":"33","author":"Chapman","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: Impact on early progression","volume":"32","author":"Isola","year":"2018","journal-title":"Leukemia"},{"key":"ref_58","first-page":"3935","article-title":"Identification of metabolic biomarkers to predict treatment outcome and disease progression in multiple myeloma","volume":"10","author":"Zhao","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Walk, J.C., Ayati, B.P., and Holstein, S.A. (2019). Modeling the effects of multiple myeloma on renal function. Sci. Rep., 9.","DOI":"10.1038\/s41598-018-38129-7"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100996","DOI":"10.1016\/j.eclinm.2021.101030","article-title":"Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study","volume":"38","author":"Lees","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Carlisi, M., Lo Presti, R., Mancuso, S., Siragusa, S., and Caimi, G. (2023). Calculated whole blood viscosity and albumin\/fibrinogen ratio in patients with a new diagnosis of multiple myeloma: Relationships with some prognostic predictors. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030964"},{"key":"ref_62","first-page":"211","article-title":"The effect of bortezomib-combined chemotherapy on multiple myeloma and VEGF, IL-6 and IL-17","volume":"22","author":"Nie","year":"2020","journal-title":"J. Clin. Transfus. Lab. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rosa-Rosa, J.M., Cuenca, I., Medina, A., V\u00e1zquez, I., S\u00e1nchez-delaCruz, A., Buenache, N., and Mart\u00ednez-L\u00f3pez, J. (2022). NGS-based molecular karyotyping of multiple myeloma: Results from the GEM12 clinical trial. Cancers, 14.","DOI":"10.3390\/cancers14205169"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.2147\/OTT.S205922","article-title":"Progress in the identification of gene mutations involved in multiple myeloma","volume":"12","author":"Hu","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: An International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bbagen.2019.03.001","article-title":"Serum protein N-glycosylation changes in multiple myeloma","volume":"1863","author":"Zhang","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood.2021013794","article-title":"Redefining nonmeasurable multiple myeloma using mass spectrometry","volume":"139","author":"Giles","year":"2022","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1097\/HS9.0000000000000758","article-title":"Retrospective longitudinal monitoring of multiple myeloma patients by mass spectrometry using archived serum protein electrophoresis gels and de novo sequence analysis","volume":"6","author":"Noori","year":"2022","journal-title":"Hemasphere"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Dunphy, K., Dowling, P., Bazou, D., and O\u2019Gorman, P. (2021). Current methods of post-translational modification analysis and their applications in blood cancers. Cancers, 13.","DOI":"10.3390\/cancers13081930"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wang, H., Liu, H., Sun, C., Liu, C., Jiang, T., Yin, Y., and Hu, Y. (2021). Nanoparticles dual targeting both myeloma cells and cancer-associated fibroblasts simultaneously to improve multiple myeloma treatment. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020274"},{"key":"ref_74","unstructured":"Mankotia, P., Verma, K., Sharma, K., Sharma, V., Kumar, V., and Sehgal, R. (2023). Mass spectroscopy in biomedical nanotechnology. Analytical Techniques for Biomedical Nanotechnology, IOP Publishing. Available online: https:\/\/iopscience.iop.org\/book\/edit\/978-0-7503-3379-5\/chapter\/bk978-0-7503-3379-5ch8."},{"key":"ref_75","first-page":"1272","article-title":"The impact of the bone marrow microenvironment on multiple myeloma","volume":"42","author":"Hou","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/MNM.0000000000001259","article-title":"99mTc-sestamibi SPECT\/CT and 18F-FDG-PET\/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma","volume":"41","author":"Mosci","year":"2020","journal-title":"Nucl. Med. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: How? When?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1016\/j.biomaterials.2012.02.060","article-title":"Long-term multimodal imaging of tumor draining sentinel lymph nodes using mesoporous silica-based nanoprobes","volume":"33","author":"Huang","year":"2012","journal-title":"Biomaterials"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-020-00965-4","article-title":"In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma","volume":"13","author":"Omstead","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Liang, H., Li, Y., Liu, C., Wang, H., Ren, Y., Sun, F., and Zhou, Y. (2025). Raman spectroscopy of dried serum for the detection of rapid noninvasive multiple myeloma. Spectrochim. Acta A Mol. Biomol. Spectrosc., 328.","DOI":"10.1016\/j.saa.2024.125448"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11307-020-01542-4","article-title":"Preclinical development of near-infrared-labeled CD38-targeted daratumumab for optical imaging of CD38 in multiple myeloma","volume":"23","author":"Cho","year":"2021","journal-title":"Mol. Imaging Biol."},{"key":"ref_82","unstructured":"Mosci, C. (2020). SPECT\/CT com Sestamibi-99mTc e PET\/CT com FDG-18F na Detec\u00e7\u00e3o de Les\u00f5es no Mieloma M\u00faltiplo. [Doctoral Dissertation, Universidade Estadual de Campinas (UNICAMP)]."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ajh.25215","article-title":"Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein","volume":"93","author":"Tschautscher","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood.2019000671","article-title":"Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease","volume":"133","author":"Lahuerta","year":"2019","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Lahuerta","year":"2014","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: The MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_92","unstructured":"Singh, V.K., and Chandra, R. (2024). T\u00e9cnicas moleculares para el diagn\u00f3stico del c\u00e1ncer. Acad. Med., 1\u201318."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Kapoor, N., Metray, A., Bandichhor, R., and Choudhury, S.D. (2025). Melphalan: Uses, side effects, current research, and precautions. Hazardous Chemicals, Elsevier.","DOI":"10.1016\/B978-0-323-95235-4.00083-9"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1177\/1078155218804042","article-title":"Evaluating the adverse effects of melphalan formulations","volume":"25","author":"Xiang","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_96","unstructured":"Ogino, M.H., and Tadi, P. (2020). Cyclophosphamide, StatPearls Publishing. Available online: https:\/\/europepmc.org\/article\/NBK\/nbk553087."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Asatsuma-Okumura, T., Ito, T., and Handa, H. (2020). Molecular mechanisms of the teratogenic effects of thalidomide. Pharmaceuticals, 13.","DOI":"10.3390\/ph13050095"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/mco.2023.2705","article-title":"Lenalidomide use in multiple myeloma","volume":"20","author":"Zhang","year":"2023","journal-title":"Mol. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Engelhardt, M., Ajayi, S., Reinhardt, H., M\u00fcller, S.J., Dold, S.M., and W\u00e4sch, R. (2018). Pomalidomide. Small Molecules in Hematology, Springer.","DOI":"10.1007\/978-3-319-91439-8_8"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2147\/CMAR.S150653","article-title":"Carfilzomib for relapsed and refractory multiple myeloma","volume":"11","author":"Groen","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/14656566.2018.1528229","article-title":"Ixazomib for the treatment of multiple myeloma","volume":"19","author":"Richardson","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: Past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation therapy for solitary plasmacytoma and multiple myeloma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Elsayad, K., Oertel, M., K\u00f6nig, L., H\u00fcske, S., Le Ray, E., Meheissen, M.A., and Eich, H.T. (2020). Maximizing the clinical benefit of radiotherapy in solitary plasmacytoma: An international multicenter analysis. Cancers, 12.","DOI":"10.3390\/cancers12030676"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/COC.0000000000000734","article-title":"Long-term outcomes after definitive radiation therapy for solitary plasmacytoma","volume":"43","author":"Curry","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/ajco.13783","article-title":"Large variation in radiation therapy fractionation for multiple myeloma in Australia","volume":"19","author":"Ong","year":"2023","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Guerini, A.E., Tucci, A., Alongi, F., Mataj, E., Belotti, A., Borghetti, P., and Buglione, M. (2022). RR Myelo POINT: A retrospective single-center study assessing the role of radiotherapy in the management of multiple myeloma and possible interactions with concurrent systemic treatment. Cancers, 14.","DOI":"10.3390\/cancers14092273"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3324\/haematol.2019.243451","article-title":"Towards individualized radiation therapy in multiple myeloma","volume":"105","author":"Momm","year":"2020","journal-title":"Haematologica"},{"key":"ref_110","first-page":"147","article-title":"The changing landscape of multiple myeloma treatment: A European perspective","volume":"10","author":"Caers","year":"2018","journal-title":"Cancers"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14712598.2022.2145882","article-title":"Elotuzumab in multiple myeloma","volume":"23","author":"Bruzzese","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14712598.2023.2193289","article-title":"Isatuximab in multiple myeloma","volume":"23","author":"Martino","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Zhang, C., Kuo, J.C.T., Huang, Y., Hu, Y., Deng, L., Yung, B.C., and Lee, R.J. (2023). Optimized liposomal delivery of bortezomib for advancing treatment of multiple myeloma. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15122674"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better?","volume":"34","author":"Raje","year":"2020","journal-title":"Leukemia"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14656566.2019.1707184","article-title":"Selinexor for the treatment of multiple myeloma","volume":"21","author":"Podar","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1182\/blood.V126.23.1798.1798","article-title":"Tuning T cell affinity improves efficacy and safety of anti-CD38\u00d7anti-CD3 bispecific antibodies in monkeys\u2014A potential therapy for multiple myeloma","volume":"126","author":"Moore","year":"2015","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/acsomega.2c07555","article-title":"Liposome-encapsulated melphalan exhibits potent antimyeloma activity and reduced toxicity","volume":"8","author":"Lin","year":"2022","journal-title":"ACS Omega"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jconrel.2022.07.015","article-title":"Anti-angiogenic nano-delivery system promotes tumor vascular normalizing and micro-environment reprogramming in solid tumor","volume":"349","author":"Shen","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","article-title":"Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma","volume":"11","author":"Federico","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Nigro, A., Frattaruolo, L., Fava, M., De Napoli, I., Greco, M., Comand\u00e8, A., De Santo, M., Pellegrino, M., Ricci, E., and Giordano, F. (2020). Bortezomib-loaded mesoporous silica nanoparticles selectively alter metabolism and induce death in multiple myeloma cells. Cancers, 12.","DOI":"10.3390\/cancers12092709"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e2215711120","DOI":"10.1073\/pnas.2215711120","article-title":"In vivo bone marrow microenvironment siRNA delivery using lipid\u2013polymer nanoparticles for multiple myeloma therapy","volume":"120","author":"Riley","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41408-023-00955-y","article-title":"BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma","volume":"13","author":"Dutta","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-024-01636-4","article-title":"Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone and minimal residual disease in multiple myeloma","volume":"17","author":"Hose","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.21873\/anticanres.13225","article-title":"Intense uptake of liposomal curcumin by multiple myeloma cell lines: Comparison to normal lymphocytes, red blood cells, and chronic lymphocytic leukemia cells","volume":"39","author":"Bolger","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"12601","DOI":"10.1063\/5.0180225","article-title":"Biomimetic platelet nanoparticles encapsulated with proteasome inhibitor bortezomib for multiple myeloma treatment","volume":"11","author":"Gao","year":"2023","journal-title":"APL Mater."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s13346-022-01268-6","article-title":"A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma","volume":"13","author":"Metselaar","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1208\/s12249-021-02177-6","article-title":"Vitamin E oil incorporated liposomal melphalan and simvastatin: Approach to obtain improved physicochemical characteristics of hydrolysable melphalan and anticancer activity in combination with simvastatin against multiple myeloma","volume":"23","author":"Sambamoorthy","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2409895","DOI":"10.1002\/advs.202409895","article-title":"Targeted delivery of c(RGDfk)\u2013modified liposomes to bone marrow through in vivo hitchhiking neutrophils for multiple myeloma therapy","volume":"12","author":"Liu","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1535-7163.MCT-15-0867","article-title":"Dual carfilzomib and doxorubicin\u2013loaded liposomal nanoparticles for synergistic efficacy in multiple myeloma","volume":"15","author":"Ashley","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_132","unstructured":"Mordor Intelligence (2025, November 20). Nanotechnology Drug Delivery Market\u2014Size, Share, Trends & Industry Report (2030). Available online: https:\/\/www.mordorintelligence.com\/industry-reports\/nanotechnology-drug-delivery-market."},{"key":"ref_133","unstructured":"PharmiWeb.com (2025, November 20). Nanomedicine Market Set for Robust Growth, Poised to Reach USD 1,022.5 Billion by 2035. Available online: https:\/\/www.pharmiweb.com\/press-release\/2025-04-10\/nanomedicine-market-set-for-robust-growth-poised-to-reach-usd-10225-billion-by-2035."},{"key":"ref_134","unstructured":"Precedence Research (2025, November 20). Nanotechnology Drug Delivery Market Revenue, Top Companies, Report 2033. Available online: https:\/\/www.precedenceresearch.com\/press-release\/nanotechnology-drug-delivery-market."},{"key":"ref_135","first-page":"1183","article-title":"Q&A: Translational cancer nanomedicine","volume":"16","author":"Dobrovolskaia","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2217\/nnm-2019-0130","article-title":"Cost-effectiveness of nanomedicine: Estimating the real size of nano-costs","volume":"14","author":"Bosetti","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ctrv.2015.05.009","article-title":"Local hyperthermia combined with radiotherapy and\/or chemotherapy: Recent advances and promises for the future","volume":"41","author":"Datta","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_138","unstructured":"National Cancer Institute (2025, November 20). CAR T-Cell Therapy Approved Treatments, Available online: https:\/\/www.cancer.gov\/about-cancer\/treatment\/research."},{"key":"ref_139","first-page":"630","article-title":"Anti-BCMA CAR T-cell therapy in relapsed or refractory multiple myeloma","volume":"386","author":"Raje","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40259-022-00557-3","article-title":"The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US","volume":"36","author":"Ghanem","year":"2022","journal-title":"BioDrugs"},{"key":"ref_141","unstructured":"La Vanguardia (2025, November 21). The Hospital Uses a Publicly Funded CAR-T Therapy for Multiple Myeloma for the First Time in Europe. Available online: https:\/\/www.lavanguardia.com\/vida."},{"key":"ref_142","first-page":"3726","article-title":"Delivery of small interfering RNA and microRNA using lipid nanoparticles for cancer therapy","volume":"17","author":"Cheng","year":"2020","journal-title":"Mol. Pharm."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/12\/1570\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:13:49Z","timestamp":1764947629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/12\/1570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":142,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["pharmaceutics17121570"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17121570","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}